Roche’s Top-line Results on Track to Meet Guidance
Roche reported top-line results for the third quarter that put it on track to meet our expectations for the full year. Roche’s oncology drug portfolio and diagnostics segment form the basis of its personalized medicine strategy, feeding into the firm’s strong intangible assets and wide economic moat. At constant currencies, Roche’s sales were up 8%…
